Johnson Johnson Aktie

199,38 EUR +1,86 EUR +0,94 %

14:17:21

STU

228,51 USD -5,55 USD -2,37 %

vorbörslich14:15:33

BTT

Johnson Johnson jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.480,04 Mrd. EUR

KGV18,82Div. Rendite2,48%

WKN853260

ISINUS4781601046

SymbolJNJ

Johnson Johnson Aktien News

Sortieren:Datum Meistgelesen

11.06.25PR NewswireNew data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

03.06.25PR NewswireDARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma ...

03.06.25PR NewswireSingle infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

03.06.25PR NewswireEarly results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients

03.06.25PR NewswireJohnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC

21.05.25PR NewswireU.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma

09.05.25PR NewswireIcotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis

05.05.25PR NewswireTREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

05.05.25PR NewswireTREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

30.04.25PR NewswireJohnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasth...

26.04.25PR NewswireJohnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

26.04.25PR NewswireJohnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer

21.04.25PR NewswireJohnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA

15.04.25PR NewswireNYSE Content Advisory: Pre-Market update + Bank of America beats earnings estimates

10.04.25PR NewswireIcotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill

08.04.25PR NewswireJohnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)

04.04.25PR NewswireTREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arth...

26.03.25PR NewswireRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer

26.03.25PR NewswireNew nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

20.03.25PR NewswireU.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Croh...

20.03.25PR NewswireRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025

18.03.25PR NewswireNipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now rec...

10.03.25PR NewswireHealth Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

10.03.25PR NewswireIcotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients

08.03.25PR NewswireIcotrokinra results show potential to set a new standard of treatment in plaque psoriasis

21.02.25PR NewswireTREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis

13.02.25PR NewswireNew nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases

28.01.25PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

23.01.25PR NewswireJohnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colour

23.01.25PR NewswireFindings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology

21.01.25PR NewswireSPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression

16.01.25PR NewswireRYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

15.01.25PR NewswireNew Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer

09.01.25PR NewswireNipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis

08.01.25PR NewswireJohnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease

07.01.25PR NewswireRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib

10.12.24PR NewswireCARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study

Johnson Johnson News

Johnson Johnson News: auf dieser Seite finden Sie alle Johnson Johnson News und Nachrichten zur Johnson Johnson Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Johnson Johnson News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Johnson Johnson News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.